CAS: 1299440-37-1 - Immunoglobulin G1, anti-(human CD19 (antigen)) (human monoclonal MEDI-551 heavy chain), disulfide with human monoclonal MEDI-551 κ-chain, dimer
Formula:Unspecified
- Sinonimi:
- Uplizna
- Inebilizumab-cdon
- Immunoglobulin G1, anti-(human CD19 (antigen)) (human monoclonal MEDI-551 heavy chain), disulfide with human monoclonal MEDI-551 κ-chain, dimer
- Inebilizumab
- MEDI 551
| Marchio | Dati del prodotto | Purezza | Fascia di prezzo | Consegna prevista |
|---|---|---|---|---|
 | Inebilizumab REF: TM-T76713CAS: 1299440-37-1 | SDS-PAGE:99.3%;SEC-HPLC:96.2% | 184,00 €~2.135,00 € | Mar 15 Ott 24 |
 | Inebilizumab REF: 3D-CLA1393CAS: 1299440-37-1 | - - - | Prezzo su richiesta | Ven 25 Ott 24 |
Inebilizumab
CAS:1299440-37-1
Inebilizumab: humanized anti-CD19 antibody, enhances cytotoxicity against B cells, treats autoimmune diseases like MS.
Purezza:
SDS-PAGE:99.3%;SEC-HPLC:96.2%
Colore e forma:
Solid
Peso molecolare:
Approximately 146.60 kDa
Ref: TM-T76713
| 1mg | 184,00 € | ||
| 5mg | 480,00 € | ||
| 10mg | 770,00 € | ||
| 25mg | 1.175,00 € | ||
| 50mg | 1.570,00 € | ||
| 100mg | 2.135,00 € |
Consegna stimata in Stati Uniti, il Martedì 15 Ottobre 2024
Inebilizumab
CAS:1299440-37-1
Anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cell.
Ref: 3D-CLA1393
| Dimensione non definita | Prezzo su richiesta |
Consegna stimata in Stati Uniti, il Venerdì 25 Ottobre 2024
